New response criteria for lymphomas in clinical trials

Annals of Oncology

Volumn 19, Issue SUPPL. 4, 2008, Pages

  Cheson, B D ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER THERAPY; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHOMA; NOTE; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; CLASSIFICATION; INSTRUMENTATION; METHODOLOGY; PATHOLOGY; REVIEW; STANDARD; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 48149110535     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn191     Document Type: Note

References (55)

1. Cheson BD, Horning SJ, Coiffier B et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
2. Surbone A, Longo DL, DeVita VT Jr et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988; 6: 1832-1837.
3. Radford JA, Cowan RA, Flanagan M et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6: 940-946.
4. Bangerter M, Moog F, Buchmann I et al. Whole-body 2-[18F]-fluoro-2-deoxy-Dglucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-1122.
5. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19: 414-419.
6. Spaepen K, Stroobants S, Dupont P et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53-59.
7. Spaepen K, Stroobants S, Dupont P et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356-1363.
8. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001; 86: 266-273.
9. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-433.
10. Jerusalem G, Beguin Y, Najjar F et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825-830.
11. Jerusalem G, Warland V, Najjar F et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
12. Zinzani PL, Magagnoli M, Chierichetti F et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10: 1141-1143.
13. Weihrauch MR, Re D, Scheidhauer K et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001; 98: 2930-2934.
14. Naumann R, Vaic A, Beuthien-Baumann B et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793-800.
15. Kostakoglu L, Leonard JP, Kuji I et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94: 879-888.
16. Naumann R, Beuthien-Baumann B, Reiss A et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004; 90: 620-625.
17. Munker R, Glass J, Griffeth LK et al. Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. Ann Oncol 2004; 15: 1699-1704.
18. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523.
19. Juweid M, Wiseman GA, Vose JM et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop criteria (IWC) and 18F-fluorodeoxyglucose positron emission tomography (PET). J Clin Oncol 2005; 23: 4652-4661.
20. Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381.
21. Hutchings M, Loft A, Hansen M et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica 2006; 91: 482-489.
22. Querellou S, Valette F, Bodet-Milin C et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol 2006; 85: 759-767.
23. Gallamini A, Rigacci L, Merli F et al. Predictive value of positron emission tomography performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475-481.
24. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59.
25. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: Consensus recommendations of the Imaging Subcommittee of the International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578.
26. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
27. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007; 110: 3507-3516.
28. Newman JS, Francis JR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 190: 111-116.
29. Thill R, Neuerburg J, Fabry U et al. Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin 1997; 36: 234-239.
30. Moog F, Bangerter M, Diederichs CG et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]-D-glucose)FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
31. Moog F, Bangerter M, Diederichs CG et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206: 475-481.
32. Buchmann I, Reinhardt M, Elsner K et al. 2-(fluorine-18)fluoro-2-deoxy-Dglucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91: 889-899.
33. Blum RH, Seymour JF, Wirth A, MacManus M et al. Frequent impact of [18F] Fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Clin Lymphoma 2004; 4: 43-49.
34. Partridge S, Timothy A, O'Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279.
35. Weihrauch MR, Re D, Bischoff S et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002; 81: 20-25.
36. Menzel C, Dobert N, Mitrou P et al. Positron emission tomography for the staging of Hodgkin's lymphoma - increasing the body of evidence in favor of the method. Ann Oncol 2002; 41: 430-436.
37. Schaefer NG, Hany TF, Taverna C et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology 2004; 232: 823-829.
38. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005; 104: 1066-1074.
39. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. Blood 1998; 16: 603-609.
40. Carr R, Barrington SF, Madan B et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91: 3340-3346.
41. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: A meta-analysis. J Nucl Med 2005; 46: 958-963.
42. Rodriguez-Vigil B, Gomez-Leon N, Pinilla I et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 2006; 47: 1643-1648.
43. Freudenberg LS, Antoch G, Schütt P et al. FDG-PET/CT in restaging of patients with lymphoma. Eur J Nuclear Med Mol Imaging 2004; 31: 325-329.
44. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: Initial experience. Radiology 2005; 237: 1038-1045.
45. Zinzani PL, Tani M, Fanti S et al. Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17: 1296-1300.
46. Kostakoglu L, Goldsmith SJ, Leonard JP et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107: 2678-2687.
47. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
48. Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123-130.
49. Zinzani PL, Stefoni V, Ambrosini V et al. FDG-PET in the serial assessment of patients with lymphoma in complete remission. Blood 2007; 110(part 1): 71a (Abstr 216).
50. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991; 9: 1196-1203.
51. Oh YK, Ha CS, Samuels BI, Cabanillas F, Hess MA, Cox JD. Stages I-III follicular lymphoma: Role of CT of the abdomen and pelvis in follow-up studies. Radiology 1999; 210: 483-486.
52. Foltz LM, Song KW, Connors JM. Who actually detects relapse in Hodgkin lymphoma: Patient or physician. Blood 2004; 104(part 1): 853-4a(Abstr 3124).
53. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: A retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006; 17: 909-913.
54. Lewis PJ, Salama A. Uptake of fluorine-18-flouorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35: 1647-1649.
55. Castellucci P, Nanni C, Farsad M et al. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 2005; 26: 689-694.